Ambalal Sarabhai

Which are the latest news on Ambalal Sarabhai?

Why is Ambalal Sarabhai Enterprises Ltd falling/rising?

As of 05-Sep, Ambalal Sarabhai Enterprises Ltd's stock price is at 43.72, down 0.36%. While the stock has recently declined, it has shown strong long-term growth with a year-to-date increase of 52.97%, outperforming the Sensex.

As of 05-Sep, Ambalal Sarabhai Enterprises Ltd's stock price is currently at 43.72, reflecting a decrease of 0.16 (-0.36%). The stock has been experiencing a downward trend, having fallen for the last two consecutive days, resulting in a total decline of 2.88% during this period. Additionally, today's performance indicates that the stock has underperformed its sector by 0.42%. <BR><BR>Despite the recent decline, the stock has shown positive performance over longer periods, with a year-to-date increase of 52.97% compared to a 10.21% decline in the Sensex. Over the past month, the stock has risen by 3.06%, while the Sensex has decreased by 2.44%. This suggests that, although the stock is currently facing a short-term decline, it has performed well relative to the market over longer time frames.<BR><BR>Investor participation appears to be increasing, as evidenced by a rise in delivery volume by 18.83% against the 5-day average. However, the stock's moving averages indicate mixed signals; it is above the 50-day, 100-day, and 200-day moving averages but below the 5-day and 20-day moving averages, which may contribute to the current volatility in its price. Overall, the recent decline in stock price can be attributed to short-term market movements and the stock's recent performance, despite its strong long-term growth.

Who are in the management team of Ambalal Sarabhai?

The management team of Ambalal Sarabhai includes Kartikeya V Sarabhai (Chairman & Wholetime Director), Anil H Parekh (Non Executive Director), Ashwin P Hathi, Chaula Shastri, Chandrashekhar B. Bohra, Mayur K Swedia (all Independent Directors), Damodar Sejpal (Company Secretary), and Brijesh Khandelwal (Director). They oversee the company's operations and strategic direction.

The management team of Ambalal Sarabhai includes the following individuals:<BR><BR>1. **Kartikeya V Sarabhai** - Chairman & Wholetime Director<BR>2. **Anil H Parekh** - Non Executive Director<BR>3. **Ashwin P Hathi** - Independent Director<BR>4. **Chaula Shastri** - Whole-time Director<BR>5. **Chandrashekhar B. Bohra** - Independent Director<BR>6. **Damodar Sejpal** - Company Secretary & Compliance Officer<BR>7. **Mayur K Swedia** - Independent Director<BR>8. **Brijesh Khandelwal** - Director and Additional Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Ambalal Sarabhai do?

Ambalal Sarabhai Enterprises Ltd is a micro-cap Indian company in the Pharmaceuticals & Biotechnology sector, manufacturing and marketing pharmaceutical and diagnostic products. As of June 2026, it reported net sales of 44 Cr and a net profit of 4 Cr, with a market cap of INR 337 Cr.

Overview: <BR>Ambalal Sarabhai Enterprises Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, engaged in manufacturing and marketing pharmaceutical, molecular diagnostics, and electronics products.<BR><BR>History: <BR>Incorporated on June 5, 1978, Ambalal Sarabhai Enterprises Ltd is one of the oldest pharmaceutical healthcare companies in India. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 44 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 4 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 337 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 24.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.23 <BR>Return on Equity: 11.67% <BR>Price to Book: 2.11 <BR><BR>Contact Details: <BR>Address: Shanti Sadan, Mirzapur Road Ahmedabad Gujarat : 380001 <BR>Tel: 91-79-25507671/25507073 <BR>Email: ketanadhvaryu@sarabhai.co.in <BR>Website: http://www.ase.life

Who are the peers of the Ambalal Sarabhai?

Ambalal Sarabhai's peers include Jenburkt Pharma, Transchem, Haleos Labs Limi, and others, with varying management risks and growth rates. Notably, Transchem has the highest 1-year return at 604.40%, while Ambalal Sarabhai's return is 42.39%.

Peers: The peers of Ambalal Sarabhai are Jenburkt Pharma, Transchem, Haleos Labs Limi, Medico Remedies, Medicamen Biotec, Trident Lifeline, Gennex Lab., BDH Industries, Everest Organics, and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jenburkt Pharma and BDH Industries, while Good management risk is found at Medico Remedies. Average management risk is present at Transchem, Haleos Labs Limi, Medicamen Biotec, Trident Lifeline, Gennex Lab., and Everest Organics, and the rest. Below Average management risk is noted for Ambalal Sarabhai and Infinium Pharma. In terms of growth, Good growth is seen at Medico Remedies, while Below Average growth is found at Jenburkt Pharma, Transchem, Haleos Labs Limi, Medicamen Biotec, and the rest. Ambalal Sarabhai also has Below Average growth. Excellent capital structure is noted at Jenburkt Pharma, Gennex Lab., and BDH Industries, while Good capital structure is seen at Medico Remedies and Trident Lifeline. Average capital structure is present at Ambalal Sarabhai, while Below Average capital structure is found at Transchem, Haleos Labs Limi, Medicamen Biotec, and Everest Organics.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Transchem at 604.40%, while the lowest is Everest Organics at -30.60%. Ambalal Sarabhai's 1-year return of 42.39% is significantly higher than Everest Organics but lower than Transchem. Additionally, the six-month return is negative for Haleos Labs Limi, Medico Remedies, Medicamen Biotec, Trident Lifeline, Everest Organics, and Infinium Pharma.

How big is Ambalal Sarabhai?

As of 31st August, Ambalal Sarabhai Enterprises Ltd has a market capitalization of 337.00 Cr, with recent net sales of 205.50 Cr and a net profit of 13.56 Cr. Shareholder's funds are 158.36 Cr, and total assets are 277.20 Cr.

As of 31st August, Ambalal Sarabhai Enterprises Ltd has a market capitalization of 337.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 205.50 Cr and a Net Profit of 13.56 Cr.<BR><BR>For the latest annual period ending in March 2026, Shareholder's Funds amounted to 158.36 Cr, while Total Assets were reported at 277.20 Cr.

Should I buy, sell or hold Ambalal Sarabhai Enterprises Ltd?

Are Ambalal Sarabhai Enterprises Ltd latest results good or bad?

Ambalal Sarabhai Enterprises Ltd's latest results show a recovery with a net profit of ₹6.50 crores for Q4 FY26, up from a loss last year, and a 25.94% increase in net sales. However, concerns about sustainability due to reliance on non-operating income and weak capital efficiency lead to a cautious outlook, resulting in a "SELL" rating.

Ambalal Sarabhai Enterprises Ltd's latest results present a mixed picture. On one hand, the company reported a consolidated net profit of ₹6.50 crores for Q4 FY26, a significant recovery from a net loss of ₹0.27 crores in the same quarter last year, reflecting a 78.57% increase quarter-on-quarter. Additionally, net sales grew by 25.94% compared to the previous quarter, reaching ₹65.49 crores, which is the highest quarterly revenue in seven quarters.<BR><BR>However, the improvement in profitability was largely driven by non-operating income, which accounted for a substantial 41.76% of profit before tax. This raises concerns about the sustainability and quality of the earnings. The operating margin of 8.70% is the highest in seven quarters, but the year-on-year revenue growth of just 1.05% indicates challenges in generating consistent top-line momentum.<BR><BR>Furthermore, the company faces fundamental issues, such as weak capital efficiency, as evidenced by an average return on capital employed (ROCE) of only 4.36%. The reliance on non-operating income and rising interest costs also pose risks to future profitability.<BR><BR>In summary, while the latest results show a positive turnaround in profitability, the underlying structural concerns and dependency on non-core income suggest that the overall outlook remains cautious. The company has received a "SELL" rating, reflecting these ongoing challenges.

When is the next results date for Ambalal Sarabhai Enterprises Ltd?

The next results date for Ambalal Sarabhai Enterprises Ltd is 21 May 2026.

The next results date for Ambalal Sarabhai Enterprises Ltd is scheduled for 21 May 2026.

How has been the historical performance of Ambalal Sarabhai?

Ambalal Sarabhai's historical performance shows fluctuating results, with net sales increasing from 170.28 crore in March 2023 to 196.19 crore in March 2025, but profitability declined significantly, with profit after tax falling from 12.14 crore to 4.29 crore and negative cash flow from operating activities. Total liabilities and assets both rose, indicating a stable asset base despite financial challenges.

Answer:<BR>The historical performance of Ambalal Sarabhai shows a fluctuating trend in key financial metrics over the years, with notable changes in revenue and profitability.<BR><BR>Breakdown:<BR>Ambalal Sarabhai's net sales increased from 170.28 crore in March 2023 to 196.19 crore in March 2025, reflecting a growth trend. However, the total operating income showed a decline from 196.75 crore in March 2022 to 196.19 crore in March 2025. The company's total expenditure, excluding depreciation, rose from 161.71 crore in March 2023 to 188.10 crore in March 2025, impacting operating profit, which decreased from 21.06 crore in March 2023 to 19.47 crore in March 2025. Profit before tax also declined from 15.86 crore in March 2023 to 4.19 crore in March 2025, while profit after tax fell from 12.14 crore to 4.29 crore in the same period. The consolidated net profit showed a similar downward trend, decreasing from 11.45 crore in March 2023 to 4.93 crore in March 2025. On the balance sheet, total liabilities increased from 245.74 crore in March 2023 to 268.23 crore in March 2025, while total assets rose from 245.74 crore to 268.23 crore, indicating a stable asset base despite rising liabilities. Cash flow from operating activities turned negative, dropping from 5 crore in March 2023 to -17 crore in March 2025, which reflects challenges in cash generation. Overall, while revenue showed some growth, profitability and cash flow faced significant pressures during this period.

Who are the top shareholders of the Ambalal Sarabhai?

The top shareholders of Ambalal Sarabhai are Sarabhai Holdings Private Limited with 25.76%, individual investors with 57.42%, and Haryana Containers Limited as the largest public shareholder at 1.61%. There are no pledged promoter holdings or mutual funds involved.

The top shareholders of Ambalal Sarabhai include Sarabhai Holdings Private Limited, which holds the highest stake at 25.76%. Individual investors collectively own 57.42% of the company. Additionally, Haryana Containers Limited is the highest public shareholder with a holding of 1.61%. There are also two foreign institutional investors (FIIs) with a combined holding of 0.38%. Notably, there are no pledged promoter holdings and no mutual funds currently holding shares in the company.

Is Ambalal Sarabhai overvalued or undervalued?

As of June 2, 2025, Ambalal Sarabhai is considered an attractive investment due to its undervalued status, with a PE ratio of 23.05, a PEG ratio of 0.28 indicating strong growth potential, and a competitive ROE of 8.52%, despite recent underperformance against the Sensex.

As of 2 June 2025, the valuation grade for Ambalal Sarabhai has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued, particularly given its price-to-earnings (PE) ratio of 23.05, a price-to-book value of 1.96, and an EV to EBITDA ratio of 38.95. These ratios suggest that the stock is trading at a reasonable valuation compared to its earnings and book value.<BR><BR>In comparison to its peers, Ambalal Sarabhai's PE ratio aligns closely with the industry average, while its PEG ratio of 0.28 indicates strong growth potential relative to its price. Notably, its return on equity (ROE) stands at 8.52%, which is competitive within the pharmaceuticals and biotechnology sector. Despite recent underperformance against the Sensex, particularly in the year-to-date and one-year periods, the overall valuation metrics suggest that Ambalal Sarabhai presents a compelling investment opportunity at its current price of 36.70.

What is the technical trend for Ambalal Sarabhai?

As of June 4, 2025, Ambalal Sarabhai's technical trend has shifted to bearish, driven by daily moving averages and Bollinger Bands indicating bearish conditions, despite mixed signals from the MACD and KST across different time frames.

As of 4 June 2025, the technical trend for Ambalal Sarabhai has changed from mildly bearish to bearish. The current stance is bearish with moderate strength, primarily driven by the daily moving averages indicating a bearish trend and both weekly and monthly Bollinger Bands also signaling bearish conditions. The MACD shows a mildly bullish signal on the weekly chart but is mildly bearish on the monthly, suggesting mixed signals across time frames. The KST aligns with this by being mildly bullish weekly but mildly bearish monthly. Overall, the indicators reflect a bearish sentiment, particularly in the short-term daily analysis.

Has Ambalal Sarabhai declared dividend?

No Dividend History Available